

Details	Title	Authors	Identifiers
Nat Commun. 2017 Jul 24;8(1):103. doi: 10.1038/s41467-017-00147-w.	Evasion of immunosurveillance by genomic alterations of PPAR $\beta$ /RXR $\alpha$ in bladder cancer.	Korpal M, Puyang X, Jeremy Wu Z, Seiler R, Furman C, Oo HZ, Seiler M, Irwin S, Subramanian V, Julie Joshi J, Wang CK, Rimkunas V, Tortora D, Yang H, Kumar N, Kuznetsov G, Matijevic M, Chow J, Kumar P, Zou J, Feala J, Corson L, et al.	PMID:28740126   PMID:PMCS524640
EBioMedicine. 2017 Apr;18:83-93. doi: 10.1016/j.ebiom.2017.04.006. Epub 2017 Apr 5.	c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.	Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, Rennie PS, Yegnasubramanian S, DeMarzo AM, Mills IG.	PMID:28412251   PMID:PMCS405195
Eur Urol. 2017 Jul;72(1):142-150. doi: 10.1016/j.eururo.2017.03.021. Epub 2017 Apr 10.	An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.	Seiler R, Oo HZ, Tortora D, Clausen TM, Wang CK, Kumar G, Pereira MA, Årum-Madsen MS, Agerbæk MÅ, Gustavsson T, Nordmaj MA, Rich JR, Lallous N, Fazli L, Lee SS, Douglas J, TodenhÄffer T, Esfandnia S, Battsogt D, Babcock JS, Al-Nakouzi N, Crabb SJ, et al.	PMID:28408175
PLoS One. 2017 Feb 24;12(2):e0172048. doi: 10.1371/journal.pone.0172048. eCollection 2017.	Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.	Blute ML Jr, Damaschke N, Wagner J, Yang B, Gleave M, Fazli L, Shi F, Abel EJ, Downs TM, Huang W, Jarrard DF.	PMID:28234906   PMID:PMCS325224
Urology. 2017 Jun;104:242.e1-242.e8. doi: 10.1016/j.urology.2017.01.029. Epub 2017 Feb 8.	A Role for the Hedgehog Effector Gli1 in Mediating Stent-induced Ureteral Smooth Muscle Dysfunction and Apheristasis.	Janssen C, Buttyan R, Seow CY, JÄnger W, Solomon D, Fazli L, Chew BH, Lange D.	PMID:28188758
J Magn Reson Imaging. 2017 Jan 27. doi: 10.1002/jmri.25624. [Epub ahead of print]	MR measurement of luminal water in prostate gland: Quantitative correlation between MRI and histology.	Sabouri S, Fazli L, Chang SD, Savdie R, Jones EC, Goldenberg SL, Black PC, Kozlowski P.	PMID:28130866
Oncogene. 2017 Jun 15;36(24):3417-3427. doi: 10.1038/onc.2016.482. Epub 2017 Jan 16.	Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.	Tse BWC, Volpert M, Rathter E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradee J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, et al.	PMID:28092670   PMID:PMCS485179
Can Urol Assoc J. 2016 Aug;10(7-8):228-233.	Effect of contrast media on urinary cytopathology specimens.	Frees S, Bidnur S, Metcalfe M, Raven P, Chavez-Munoz C, Moskalev I, Fazli L, So A.	PMID:27878040   PMID:PMCS110417
PLoS One. 2016 Nov 15;11(11):e0165236. doi: 10.1371/journal.pone.0165236. eCollection 2016.	MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.	Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L, Brooks JD.	PMID:27846218   PMID:PMCS112958
Cancer Res. 2016 Nov 15;76(22):6701-6711. doi: 10.1158/0008-5472.CAN-16-1518. Epub 2016 Sep 22.	UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling.	Li H, Xie N, Chen R, Verreault M, Fazli L, Gleave ME, Barbier O, Dong X.	PMID:27659047
Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26.	The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.	Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.	PMID:27784708
Prostate. 2017 Feb;77(3):309-320. doi: 10.1002/pros.23269. Epub 2016 Oct 24.	Suppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.	Dejima T, Imada K, Takeuchi A, Shiota M, Leong J, Tombe T, Tam K, Fazli L, Naito S, Gleave ME, Ong CJ.	PMID:27775154
Am J Surg Pathol. 2016 Nov;40(11):1439-1456.	Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.	McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD.	PMID:27635949
Oncotarget. 2016 Nov 15;7(46):75585-75602. doi: 10.18632/oncotarget.12310.	c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.	Maina PK, Shao P, Liu Q, Fazli L, Tyler S, Nasir M, Dong X, Qi HH.	PMID:27689328   PMID:PMCS342763
Sci Rep. 2016 Sep 13;6:30555. doi: 10.1038/srep30555.	Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33.	Saranchova I, Han J, Huang H, Fenninger F, Choi KB, Munro L, Pfeifer C, Welch J, Wyatt AW, Fazli L, Gleave ME, Jefferies WA.	PMID:27619158   PMID:PMCS020406
Eur Urol Focus. 2016 Jun;2(2):180-188.	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.	Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Hurtado-Coll A, Troyer D, McKenney JK, Simko J, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD.	PMID:27617307   PMID:PMCS014432
Sens Biosensing Res. 2016 Jul;9:23-30.	Real-time and label free determination of ligand binding-kinetics to primary cancer tissue specimens; a novel tool for the assessment of biomarker targeting.	Clausen TM, Pereira MA, Oo HZ, Resende M, Gustavson T, Mao Y, Sugiura N, Liew J, Fazli L, Theander TG, Daugaard M, Salanti A.	PMID:27441183   PMID:PMCA4942562
Prostate. 2016 Nov;76(15):1409-19. doi: 10.1002/pros.23225. Epub 2016 Jun 21.	Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort.	Brooks JD, Wei W, Pollack JR, West RB, Shin JH, Sunwoo JB, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L.	PMID:27325561
Clin Genitourin Cancer. 2017 Feb;15(1):e145-e150. doi: 10.1016/j.clgc.2016.05.019. Epub 2016 May 27. No abstract available.	Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.	Annala M, Nappi L, Azad AA, Mo F, Fazli L, Chi KN, Wyatt AW.	PMID:27324055
Eur Urol. 2016 Jul;70(1):e27-e28. doi: 10.1016/j.eururo.2016.03.014. Epub 2016 Mar 31. No abstract available.	Corrigendum re: "Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer" [Eur Urol 2014;66:145-55].	Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME.	PMID:27302299
EMBO Mol Med. 2016 Jul 1;8(7):761-78. doi: 10.15252/emmm.201506059. Print 2016 Jul.	Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.	Al Nakouzi N, Wang CK, Beraldi E, Jager W, Ettinger S, Fazli L, Nappi L, Bishop J, Zhang F, Chaudhary A, Loriot Y, Gleave M.	PMID:27198502   PMID:PMCA4931290
Mod Pathol. 2016 Aug;29(8):904-14. doi: 10.1038/modpathol.2016.88. Epub 2016 May 13.	Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.	Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L, Hurtado-Coll A, McKenney JK, Simko J, Carroll PR, Gleave M, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Lance R, Troyer D, et al.	PMID:27174589   PMID:PMCA4967011
Prostate Cancer Prostatic Dis. 2016 Sep;19(3):264-70. doi: 10.1038/pcan.2016.12. Epub 2016 May 3.	Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.	Tretiakova MS, Wei W, Boyer HD, Newcomb LF, Hawley S, Auman H, Vakar-Lopez F, McKenney JK, Fazli L, Simko J, Troyer DA, Hurtado-Coll A, Thompson IM Jr, Carroll PR, Ellis WJ, Gleave ME, Nelson PS, Lin DW, True LD, Feng Z, Brooks JD.	PMID:27136741   PMID:PMCS536893
Endocrinology. 2016 May;157(5):2129-39. doi: 10.1210/en.2015-2005. Epub 2016 Mar 16.	HoxA13 Stimulates Myometrial Cells to Secrete IL-1 $\beta$ and Enhance the Expression of Contraction-Associated Proteins.	Li H, Yu Y, Shi Y, Fazli L, Slater D, Lye S, Dong X.	PMID:26982635
Oncotarget. 2016 Mar 22;7(12):14639-58. doi: 10.18632/oncotarget.7052.	Exosomes confer pro-survival signals to alter the phenotype of prostate cells in their surrounding environment.	Hosseini-Beheshti E, Choi W, Weiswald LB, Kharmate G, Ghaffari M, Roshan-Moniri M, Hassona MD, Chan L, Chin MY, Tai IT, Rennie PS, Fazli L, Tomlinson G, et al.	PMID:26840259   PMID:PMCA4924741
Clin Cancer Res. 2016 Jun 15;22(12):2981-92. doi: 10.1158/1078-0432.CCR-15-2360. Epub 2016 Jan 14.	Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy.	Hayashi T, Gust KM, Wyatt AW, Goriki A, JÄnger W, Awrey S, Li N, Oo HZ, Altamirano-Dimas M, Buttyan R, Fazli L, Matsubara A, Black PC.	PMID:26769750
Clin Cancer Res. 2016 Jun 1;22(11):2721-33. doi: 10.1158/1078-0432.CCR-15-1624. Epub 2016 Jan 11.	The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer.	Choi SY, Xue H, Wu R, Fazli L, Lin D, Collins CC, Gleave ME, Gout PW, Wang Y.	PMID:26755530
Neoplasia. 2015 Nov;17(11):805-16. doi: 10.1016/j.neo.2015.11.001.	Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.	Han KS, Raven PA, Frees S, Gust K, Fazli L, Ettinger S, Hong SJ, Kollmannsberger C, Gleave ME, So AI.	PMID:26678908   PMID:PMCA4681895
Oncotarget. 2016 Jan 12;7(2):1878-94. doi: 10.18632/oncotarget.6479.	Low P $\beta$ , $\alpha$ -adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.	Braadland PR, Grylls HH, Rømborg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, MÅ, Iandsmo GM, Svinland A, Barbier O, TaskÅn KA.	PMID:26646591   PMID:PMCA4811504
Sci Rep. 2015 Nov 13;5:15182. doi: 10.1038/srep15182.	Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.	Hu X, Garcia C, Fazli L, Gleave M, Vitek MP, Jansen M, Christensen D, Mulholland DJ.	PMID:26563471   PMID:PMCA4643319
Oncotarget. 2015 Oct 20;6(32):34038. doi: 10.18632/oncotarget.6187. No abstract available.	Erratum: Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts.	Treterola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, Altieri DC, Languino LR.	PMID:26513314   PMID:PMCA4741825
Cell Death Dis. 2015 Oct 29;6:e1955. doi: 10.1038/cddis.2015.289.	DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis.	Zhou J, Ning Z, Wang B, Yun EJ, Zhang T, Peng RC, Fazli L, Gleave M, Zeng J, Fan J, Wang X, Li L, Hsieh JT, He D, Wu K.	PMID:26512963   PMID:PMCS399177
Clin Cancer Res. 2016 Feb 1;22(3):670-9. doi: 10.1158/1078-0432.CCR-15-0190. Epub 2015 Oct 21.	Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer.	Yun EJ, Zhou J, Lin CJ, Hernandez E, Fazli L, Gleave M, Hsieh JT.	PMID:26490309   PMID:PMCA4738061
Oncotarget. 2015 Oct 27;6(33):34818-30. doi: 10.18632/oncotarget.5397.	Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2 $\beta$ pathway.	Han KS, Li N, Raven PA, Fazli L, Frees S, Ettinger S, Park KC, Hong SJ, Gleave ME, So AI.	PMID:26472187   PMID:PMCA4741492
Cancer Cell. 2015 Oct 12;28(4):500-14. doi: 10.1016/j.ccell.2015.09.003.	Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.	Salanti A, Clausen TM, Agerbæk MÅ, Al Nakouzi N, Dahlbäck M, Oo HZ, Lee S, Gustavsson T, Rich JR, Hedberg BJ, Mao Y, Barington L, Pereira MA, LoBello J, Endo M, Fazli L, Soden J, Wang CK, Sander AF, Dagli R, Thrane S, Holst PJ, et al.	PMID:26461094   PMID:PMCA4790448
J Urol. 2016 Feb;195(2):313-20. doi: 10.1016/j.juro.2015.08.087. Epub 2015 Aug 29.	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.	Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, et al.	PMID:26327354   PMID:PMCA4970462

Details	Title	Authors	Identifiers
Oncogene. 2016 May 12;35(19):2441-52. doi: 10.1038/onc.2015.309. Epub 2015 Aug 17.	Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.	Fan L, Peng G, Sahgal N, Fazli L, Gleave M, Zhang Y, Hussain A, Qi J.	PMID:26279298   PMCID:PMC4757517
Cell Rep. 2015 Aug 11;12(6):922-36. doi: 10.1016/j.celrep.2015.07.012. Epub 2015 Jul 30.	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.	Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A, Brahmabhatt S, Bell R, Adomat H, Kawai Y, Xue H, Dong X, Fazli L, Tsai H, Lotan TL, Kossai M, Mesquera JM, Rubin MA, et al.	PMID:26235627
PLoS One. 2015 Jul 14;10(7):e0132343. doi: 10.1371/journal.pone.0132343. eCollection 2015.	Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.	Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, McKenney JK.	PMID:26172920   PMCID:PMC4501723
J Biol Chem. 2015 Aug 21;290(34):20865-79. doi: 10.1074/jbc.M115.662155. Epub 2015 Jul 9.	The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.	Fan L, Peng G, Hussain A, Fazli L, Gung S, Gleave M, Qi J.	PMID:26160177   PMCID:PMC4543648
Clin Cancer Res. 2015 Nov 12;21(21):4845-55. doi: 10.1158/1078-0432.CCR-15-0866. Epub 2015 Jun 23.	siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.	Yamamoto Y, Lin PJ, Beraldi E, Zhang F, Kawai Y, Leong J, Katsumi H, Fazli L, Fraser R, Cullis PR, Gleave M.	PMID:26106075
Oncotarget. 2015 Sep 8;6(26):22060-71.	Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass.	Yang CC, Fazli L, Loguericio S, Zharkikh I, Aza-Blanc P, Gleave ME, Wolf DA.	PMID:26091350   PMCID:PMC4673146
J Urol. 2015 Oct;194(4):1120-31. doi: 10.1016/j.juro.2015.05.087. Epub 2015 Jun 3.	Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer.	Hayashi T, Seiler R, Oo HZ, Jäger W, Moskalev I, Awrey S, Dejima T, Todenhäfer T, Li N, Fazli L, Matsubara A, Black PC.	PMID:26047983
Oncotarget. 2015 Aug 28;6(25):21522-32.	Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.	Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt AW, Anderson S, Moskalev I, Haegert A, Alshalfi M, Erho N, Davicioni E, Fazli L, Li E, Collins C, Wang Y, Black PC.	PMID:26041878   PMCID:PMC4673283
Oncotarget. 2015 Jun 10;6(16):14318-28. Erratum in: Oncotarget. 2015 Oct 20;6(32):34038.	Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts.	Treterola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, Altieri DC, Linguino LR.	PMID:26015409   PMCID:PMC4546469
Prostate. 2015 Aug 1;75(11):1206-15. doi: 10.1002/pros.23003. Epub 2015 May 4.	A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.	Troyer DA, Janssens P, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA.	PMID:25939393   PMCID:PMC4475421
Oncotarget. 2015 May 20;6(14):12587-602.	Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer.	Barfeld SJ, Fazli L, Persson M, Marjaveera L, Urbanucci A, Kaukonenmi KM, Rennie PS, Ceder Y, Chabes A, Visakorpi T, Mills IG.	PMID:25869206   PMCID:PMC4494960
EMBO Mol Med. 2015 Jun;7(6):788-801. doi: 10.15252/emmm.201404509.	Divergent androgen regulation of unfolded protein response pathways drives prostate cancer.	Sheng X, Arnoldussen YJ, Storm M, Tesikova M, Nenseth HZ, Zhao S, Fazli L, Rennie P, Risberg B, WÅhre H, Danielsen H, Mills IG, Jin Y, Hotamisliligil G, Saatcioglu F.	PMID:25864123   PMCID:PMC4459818
Prostate. 2015 Jul 1;75(10):1043-50. doi: 10.1002/pros.22988. Epub 2015 Apr 1.	Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation.	Yu Y, Yang O, Fazli L, Rennie PS, Gleave ME, Dong X.	PMID:25833156
J Steroid Biochem Mol Biol. 2015 Jun;150:35-45. doi: 10.1016/j.jsbmb.2015.03.006. Epub 2015 Mar 19.	A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice.	Fokidis HB, Yieng Chin M, Ho VW, Adomat HH, Soma KK, Fazli L, Nip KM, Cox M, Krystal G, Zoubeidi A, Tomlinson Guns ES.	PMID:25797030
Mol Cancer Ther. 2015 May;14(5):1107-16. doi: 10.1158/1535-7163.MCT-14-0866. Epub 2015 Mar 4.	Hsp27 inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.	Lejj-Garolla B, Kumano M, Beraldi E, Nappi L, Rocchi P, Ionescu DN, Fazli L, Zoubeidi A, Gleave ME.	PMID:25740245
J Pathol. 2015 Jul;236(3):278-89. doi: 10.1002/path.4518. Epub 2015 Apr 7.	Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.	Wang Q, Hardie RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, Sadowski MC, Balaban S, Schreuder M, Nagarajah R, Wong JJ, Metierre C, Pinello N, Otte NJ, Lehman ML, Gleave M, Nelson CC, Bailey CG, Ritchie W, Rasko JE, Holst J.	PMID:25693838   PMCID:PMC4973854
EMBO Mol Med. 2015 Mar;7(3):315-31. doi: 10.15252/emmm.201404181.	STAMP2 increases oxidative stress and is critical for prostate cancer.	Jin Y, Wang L, Qu S, Sheng X, Kristian A, MÅllandsmo GM, PÅllmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, Risberg B, WÅhre H, Danielsen HE, Ozpolat B, Saatcioglu F.	PMID:25680860   PMCID:PMC4364948
Mol Cancer Ther. 2015 Apr;14(4):1024-34. doi: 10.1158/1535-7163.MCT-14-0771. Epub 2015 Feb 5.	Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma.	Han KS, Li N, Raven PA, Fazli L, Ettlinger S, Hong SJ, Gleave ME, So AI.	PMID:25657336
Clin Cancer Res. 2015 Apr 1;21(7):1675-87. doi: 10.1158/1078-0432.CCR-14-1108. Epub 2015 Jan 29.	Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.	Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, Al Nakouzi N, Mo F, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli L, Wang Y, Collins CC, Zoubeidi A, Gleave M.	PMID:25634993
Oncotarget. 2015 Jan 30;6(3):1806-20.	Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.	Lin D, Dong X, Wang K, Wyatt AW, Crea F, Xue H, Wang Y, Wu R, Bell RH, Haegert A, Brahmabhatt S, Hurtado-Coll A, Gout PW, Fazli L, Gleave ME, Collins CC, Wang Y.	PMID:25544761   PMCID:PMC4359333
Nat Commun. 2014 Dec 12;5:5775. doi: 10.1038/ncomms6775.	Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival.	Zhang F, Kumano M, Beraldi E, Fazli L, Du C, Moore S, Sorensen P, Zoubeidi A, Gleave ME.	PMID:25503391   PMCID:PMC4275590
NMR Biomed. 2015 Jan;28(1):124-39. doi: 10.1002/nbm.3218. Epub 2014 Nov 14.	MR elastography of prostate cancer: quantitative comparison with histopathology and repeatability of methods.	Sahebjavaher RS, Nir G, Honarvar M, Gagnon LO, Ischia J, Jones EC, Chang SD, Fazli L, Goldenberg SL, Rohling R, Kozlowski P, Sinkus R, Salcudean SE.	PMID:25395244
NMR Biomed. 2015 Jan;28(1):89-100. doi: 10.1002/nbm.3203. Epub 2014 Nov 10.	MR elastography and diffusion-weighted imaging of ex vivo prostate cancer: quantitative comparison to histopathology.	Sahebjavaher RS, Nir G, Gagnon LO, Ischia J, Jones EC, Chang SD, Yung A, Honarvar M, Fazli L, Goldenberg SL, Rohling R, Sinkus R, Kozlowski P, Salcudean SE.	PMID:25382459   PMCID:PMCS478374
Med Image Comput Comput Assist Interv. 2014;17(Pt 1):561-8.	Multi-parametric 3D quantitative ultrasound vibro-elastography imaging for detecting palpable prostate tumors.	Mohareri O, Ruzskowski A, Lobo J, Ischia J, Baghani A, Nir G, Eskandari H, Jones E, Fazli L, Goldenberg L, Moradi M, Salcudean S.	PMID:25333163
Mol Cancer Ther. 2014 Dec;13(12):2827-39. doi: 10.1158/1535-7163.MCT-13-0842. Epub 2014 Sep 29.	The tyrosinase NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer.	Ibuki N, Ghaffari M, Reuveni H, Pandey M, Fazli L, Azuma H, Gleave ME, Levitzki A, Cox ME.	PMID:25267499
J Urol. 2015 Feb;193(2):714-21. doi: 10.1016/j.juro.2014.08.110. Epub 2014 Sep 6.	Erythropoietin accelerates the regeneration of ureteral function in a murine model of obstructive uropathy.	Janssen C, Jäger W, Moskalev I, Fazli L, ThÅkroff JW, Lange D.	PMID:25200805
Genome Biol. 2014 Aug 26;15(8):426. doi: 10.1186/s13059-014-0426-y.	Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.	Wyatt AW, Mo F, Wang K, McConoghy B, Brahmabhatt S, Jong L, Mitchell DM, Johnston RL, Haegert A, Li E, Liew J, Yeung J, Shrestha R, Lapuk AV, McPherson A, Shukin R, Bell RH, Anderson S, Bishop J, Hurtado-Coll A, Xiao H, Chinnaiyan AM, et al.	PMID:25155515   PMCID:PMC4169643
Eur Urol. 2015 Jun;67(6):986-90. doi: 10.1016/j.eururo.2014.08.006. Epub 2014 Aug 20.	Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.	Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, Gleave ME, Zoubeidi A.	PMID:25151012
Int J Cancer. 2015 Feb 15;136(4):E27-38. doi: 10.1002/ijc.29147. Epub 2014 Aug 27.	The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.	Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L, Fazli L, Gleave ME, Wang Y, Rennie P, Dong X.	PMID:25138562
Oncogenesis. 2014 Aug 18;3:e115. doi: 10.1038/oncsis.2014.30.	Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer.	Zardan A, Nip KM, Thaper D, Toren P, Vahid S, Beraldi E, Fazli L, Lamoureux F, Gust KM, Cox ME, Bishop JL, Zoubeidi A.	PMID:25133482   PMCID:PMCS189960
Oncotarget. 2014 Aug 15;5(15):6425-36.	The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth.	Tsai YS, Lai CL, Lai CH, Chang KH, Wu K, Teng SF, Fazli L, Gleave M, Xiao G, Gandee L, Sharifi N, Moro L, Tzai TS, Hsieh JT.	PMID:25115390   PMCID:PMC4171641
Mol Endocrinol. 2014 Oct;28(10):1629-39. doi: 10.1210/me.2014-1078. Epub 2014 Aug 6.	Crosstalk between nuclear MET and SOX9/ $\beta$ -catenin correlates with castration-resistant prostate cancer.	Xie Y, Lu W, Liu S, Yang Q, Carver BS, Li E, Wang Y, Fazli L, Gleave M, Chen Z.	PMID:25099011   PMCID:PMC4179634
Oncotarget. 2014 Aug 30;5(16):6896-908.	The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.	Luk XU, Xue H, Cheng H, Lin D, Gout PW, Fazli L, Collins CC, Gleave ME, Wang Y.	PMID:25071009   PMCID:PMC4196171
J Urol. 2014 Dec;192(6):1842-8. doi: 10.1016/j.juro.2014.07.013. Epub 2014 Jul 18.	DHH is an independent prognosticator of oncologic outcome of clear cell renal cell carcinoma.	Wyatt AW, Thomas C, Fazli L, Hurtado-Coll A, Li E, Janssen C, Gust KM, So AI, Hainz M, Schmitdmann I, Roos FC, ThÅkroff JW, Brenner W, Black PC.	PMID:25046620
Med Phys. 2014 Jul;41(7):073505. doi: 10.1118/1.4884226.	Multiparametric 3D in vivo ultrasound vibroelastography imaging of prostate cancer: Preliminary results.	Moradi M, Mahdavi SS, Nir G, Mohareri O, Koupparis A, Gagnon LO, Fazli L, Casey RG, Ischia J, Jones EC, Goldenberg SL, Salcudean SE.	PMID:24989419
Clin Cancer Res. 2014 Sep 1;20(17):4636-46. doi: 10.1158/1078-0432.CCR-14-0305. Epub 2014 Jun 24.	miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer.	Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhou HE, Liu C, Lao K, Lu CL, Lu YT, Lichtenman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW.	PMID:24963047   PMCID:PMC4155061
PLoS One. 2014 Mar 24;9(3):e92714. doi: 10.1371/journal.pone.0092714. eCollection 2014.	Prostate stromal cells express the progesterone receptor to control cancer cell mobility.	Yu Y, Lee JS, Xie N, Li E, Hurtado-Coll A, Fazli L, Cox M, Plymate S, Gleave M, Dong X.	PMID:24664419   PMCID:PMC3963951
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4251-6. doi: 10.1073/pnas.1322198111. Epub 2014 Mar 3.	Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.	Wang S, Kollipara RK, Srivastava N, Li R, Ravindranathan P, Hernandez E, Freeman E, Humphries CG, Kapur P, Lotan Y, Fazli L, Gleave ME, Plymate SR, Raj GV, Hsieh JT, Kittler R.	PMID:24591637   PMCID:PMC3964108
Clin Exp Metastasis. 2014 Apr;31(4):435-46. doi: 10.1007/s10585-014-9638-5. Epub 2014 Feb 8.	A humanized tissue-engineered in vivo model to dissect interactions between human prostate cancer cells and human bone.	Hesami P, Holzapfel BM, Taubenberger A, Roudier M, Fazli L, Sieh S, Thibaudeau L, Gregory LS, Huttmacher DW, Clements JA.	PMID:24510218
Med Image Comput Comput Assist Interv. 2013;16(Pt 3):461-8.	Separation of benign and malignant glands in prostatic adenocarcinoma.	Rashid S, Fazli L, Boag A, Siemens R, Abolmaesumi P, Salcudean SE.	PMID:24505794
Oncotarget. 2014 Jan 30;5(2):451-61.	GATA2 as a potential metastasis-driving gene in prostate cancer.	Chiang YT, Wang K, Fazli L, Qi RZ, Gleave ME, Collins CC, Gout PW, Wang Y.	PMID:24448395   PMCID:PMC3964220

Details	Title	Authors	Identifiers
Eur Urol. 2014 Jul;66(1):145-55. doi: 10.1016/j.euro.2013.12.019. Epub 2013 Dec 29.	Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.	Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME.	PMID:24411988   PMCID:PMC4079118
Cancer Res. 2014 Feb 15;74(4):1272-83. doi: 10.1158/0008-5472.CAN-13-2921-T. Epub 2013 Dec 19.	High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.	Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmabhatt S, Mo F, Jong L, Bell RH, Anderson S, Hurtado-Coll A, Fazli L, Sharma M, Beltran H, Rubin M, Cox M, Gout PW, Morris J, Goldenberg L, Volik SV, et al.	PMID:24356420
Cancer Res. 2013 Dec 17;73(23):6963-71. doi: 10.1158/0008-5472.CAN-13-1462. Epub 2013 Oct 11.	Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.	Grosse L, PÂcquet S, Caron P, Fazli L, Rennie PS, BÂ@langer A, Barbier O.	PMID:24121496
J Natl Cancer Inst. 2013 Oct 2;105(19):1463-73. doi: 10.1093/jnci/djt241. Epub 2013 Sep 19.	Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.	Wang Q, Tiffen J, Bailey CG, Lehman ML, Ritchie W, Fazli L, Metierre C, Feng YJ, Li E, Gleave M, Buchanan G, Nelson CC, Rasko JE, Holst J.	PMID:24052624
Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1984-93. doi: 10.1158/1055-9965.EPI-13-0349. Epub 2013 Aug 27.	Protein expression of PTEN, insulin-like growth factor 1 receptor (IGF-1R), and lethal prostate cancer: a prospective study.	Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E.	PMID:23983239   PMCID:PMC3818474
Mol Cancer Ther. 2013 Nov;12(11):2342-55. doi: 10.1158/1535-7163.MCT-13-0032. Epub 2013 Aug 21.	Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.	Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A.	PMID:23966621
Clin Cancer Res. 2013 Sep 1;19(17):4740-9. doi: 10.1158/1078-0432.CCR-13-0954. Epub 2013 Jul 9.	The mechanism of DAB2IP in chemoresistance of prostate cancer cells.	Wu K, Xie D, Zou Y, Zhang T, Pong RC, Xiao G, Fazli L, Gleave M, He D, Boothman DA, Hsieh JT.	PMID:23838317   PMCID:PMC4806645
J Clin Endocrinol Metab. 2013 Jul;98(7):2887-96. doi: 10.1210/jc.2012-4000. Epub 2013 May 10.	Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control.	Yu Y, Liu L, Xie N, Xue H, Fazli L, Buttyan R, Wang Y, Gleave M, Dong X.	PMID:23666965   PMCID:PMC4078099
J Control Release. 2013 Aug 28;170(1):64-73. doi: 10.1016/j.jconrel.2013.04.012. Epub 2013 Apr 30.	Fusidic acid and rifampicin co-loaded PLGA nanofibers for the prevention of orthopedic implant associated infections.	Gilchrist SE, Lange D, Letchford K, Bach H, Fazli L, Burt HM.	PMID:23639451
Oncogene. 2014 Apr 10;33(15):1954-63. doi: 10.1038/onc.2013.143. Epub 2013 Apr 22.	The role of DAB2IP in androgen receptor activation during prostate cancer progression.	Wu K, Liu J, Tseng SF, Gore C, Ning Z, Sharifi N, Fazli L, Gleave M, Kapur P, Xiao G, Sun X, Oz OK, Min W, Alexandrakis G, Yang CR, Hsieh CL, Wu HC, He D, Xie D, Hsieh JT.	PMID:23604126
Int J Cancer. 2013 Oct 15;133(8):1955-66. doi: 10.1002/ijc.28193. Epub 2013 May 6.	TAK-441, a novel investigational smoothmoothed antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.	Ibuki N, Ghaffari M, Pandey M, Lu J, Fazli L, Kashiwagi M, Tojo H, Nakanishi O, Gleave ME, Cox ME.	PMID:23564295
PLoS One. 2013;8(3):e59536. doi: 10.1371/journal.pone.0059536. Epub 2013 Mar 26.	Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach.	JÅager W, Moskalev I, Janssen C, Hayashi T, Awrey S, Gust KM, So AI, Zhang K, Fazli L, Li E, ThÅxroff JW, Lange D, Black PC.	PMID:23555699   PMCID:PMC3608695
Cancer Cell. 2013 Mar 18;23(3):332-46. doi: 10.1016/j.ccr.2013.02.016. Erratum in: Cancer Cell. 2013 Jun 10;23(6):853. Fazli, Ladan [corrected to Fazli, Ladan].	The E3 ubiquitin ligase Slah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity.	Qj J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA.	PMID:23518348   PMCID:PMC3750989
Cancer Res. 2013 May 15;73(10):3109-19. doi: 10.1158/0008-5472.CAN-12-3979. Epub 2013 Mar 14.	Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer.	Shiota M, Bishop JL, Nip KM, Zardan A, Takeuchi A, Cordonnier T, Beraldi E, Bazov J, Fazli L, Chi K, Gleave M, Zoubeidi A.	PMID:23492367
PLoS One. 2013;8(2):e55837. doi: 10.1371/journal.pone.0055837. Epub 2013 Feb 8.	BIRC6 protein, an inhibitor of apoptosis: role in survival of human prostate cancer cells.	Low CG, Luk IS, Lin D, Fazli L, Yang K, Xu Y, Gleave M, Gout PW, Wang Y.	PMID:23409057   PMCID:PMC3568134
Transl Oncol. 2012 Dec;5(6):453-60. Epub 2012 Dec 1.	The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression.	Choucrair KA, GuÅ@ard KP, Ejdelman J, Chevalier S, Yoshimoto M, Scarlata E, Fazli L, Sircar K, Squire JA, Brimo F, Cunha IW, Aprkian A, Gleave M, Lapointe J.	PMID:23401739   PMCID:PMC3568696
Prostate. 2013 Jul;73(10):1057-68. doi: 10.1002/pros.22653. Epub 2013 Feb 6.	Expression and role of the angiotensin II AT2 receptor in human prostate tissue: in search of a new therapeutic option for prostate cancer.	Guimond MO, Battista MC, Njikoutavabi F, Carmel M, Barres V, Doueik AA, Fazli L, Gleave M, Sabbagh R, Gallo-Payet N.	PMID:23389987
Mol Ther. 2013 Apr;21(4):842-8. doi: 10.1038/mt.2012.285. Epub 2013 Jan 22.	Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus.	Moussavi M, Tearle H, Fazli L, Bell JC, Jia W, Rennie PS.	PMID:23337981   PMCID:PMC3616523
Endocr Relat Cancer. 2013 Mar 22;20(2):173-86. doi: 10.1530/ERC-12-0250. Print 2013 Apr.	IGF2 increases de novo steroidogenesis in prostate cancer cells.	Lubik AA, Gunter JH, Hollier BG, Ettinger S, Fazli L, Stylianou N, Hendy SC, Adomat HH, Gleave ME, Pollak M, Herington A, Nelson CC.	PMID:23319492
Adv Anat Pathol. 2013 Jan;20(1):39-44. doi: 10.1097/PAP.0b013e31827b665b. Review.	A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.	Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, et al.	PMID:23232570   PMCID:PMC3535290
Mol Ther. 2012 Dec;20(12):2244-56. doi: 10.1038/mt.2012.155. Epub 2012 Aug 14.	Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer.	Baylot V, Katsogiannou M, Andrieu C, Taleb D, Acunzo J, Giusiano S, Fazli L, Gleave M, Garrido C, Rocchi P.	PMID:22893039   PMCID:PMC3519986
PLoS One. 2012;7(8):e42564. doi: 10.1371/journal.pone.0042564. Epub 2012 Aug 3.	Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells.	Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, Chen D, Li Y, Guo C, Zhang B, Fazli L, Gleave M, Witte ON, Garraway IP, Wu H.	PMID:22880034   PMCID:PMC3411798
Mol Endocrinol. 2012 Sep;26(9):1496-507. doi: 10.1210/me.2011-1360. Epub 2012 Jun 28.	Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer.	Wu K, Gore C, Yang L, Fazli L, Gleave M, Pong RC, Xiao G, Zhang L, Yun EJ, Tseng SF, Kapur P, He D, Hsieh JT.	PMID:22745193   PMCID:PMC5416972
Mol Cancer Ther. 2012 Aug;11(8):1661-71. doi: 10.1158/1535-7163.MCT-12-0072. Epub 2012 Jun 6.	Cotargeting stress-activated Hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer.	Kumano M, Furukawa J, Shiota M, Zardan A, Zhang F, Beraldi E, Wiedmann RM, Fazli L, Zoubeidi A, Gleave ME.	PMID:22675041   PMCID:PMC4128402
Clin Cancer Res. 2012 Jun 15;18(12):3407-13. doi: 10.1158/1078-0432.CCR-12-0482. Epub 2012 May 2.	A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer.	Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, Murray N, Tinker A, Pollak M.	PMID:22553344
J Pathol. 2012 Jul;227(3):286-97. doi: 10.1002/path.4047.	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.	Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmabhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, Jones EC, Hach F, Hormozdiari F, Hajirasoulha I, Boutros PC, Bristow RG, Zhao Y, et al.	PMID:22553170   PMCID:PMC3659819
Anticancer Drugs. 2012 Jun;23(5):543-52. doi: 10.1097/CAD.0b013e3182835006f5.	A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer.	Musende AG, Eberding A, Wood CA, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, Tomlinson Guns S.	PMID:22481061
J Pathol. 2012 May;227(1):53-61. doi: 10.1002/path.3987. Epub 2012 Mar 21.	Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.	Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, Bell RH, Anderson S, Haegert A, Brahmabhatt S, Shukin R, Mo F, Li E, Fazli L, Hurtado-Coll A, Jones EC, Butterfield YS, Hach F, Hormozdiari F, Hajirasoulha I, Boutros PC, Bristow RG, Jones SJ, et al.	PMID:22294438   PMCID:PMC3768138
Mol Cancer Ther. 2012 Mar;11(3):775-83. doi: 10.1158/1535-7163.MCT-11-0826. Epub 2012 Jan 17.	Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.	Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH, Brahmabhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA, Demichelis F, Beltran H, Hirst M, Marra M, Maher CA, Chinnaiyan AM, Gleave M, et al.	PMID:22252602   PMCID:PMC3691697
Prostate. 2012 Sep 1;72(12):1286-94. doi: 10.1002/pros.22477. Epub 2011 Dec 27.	TP53INP1 as new therapeutic target in castration-resistant prostate cancer.	Giusiano S, Baylot V, Andrieu C, Fazli L, Gleave M, Iovanna JL, Taranger-Charpin C, Garcia S, Rocchi P.	PMID:22213058
J Clin Endocrinol Metab. 2012 Mar;97(3):E428-32. doi: 10.1210/jc.2011-2064. Epub 2011 Dec 14.	Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.	PÂcquet S, Fazli L, Grosse L, Verreault M, TÅThu B, Rennie PS, BÂ@langer A, Barbier O.	PMID:22170718
Prostate. 2012 Jun 1;72(8):875-85. doi: 10.1002/pros.21490. Epub 2011 Oct 5.	Cardipoda enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.	Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.	PMID:22072572
Cancer Lett. 2012 Feb 1;315(1):38-47. doi: 10.1016/j.canlet.2011.10.003. Epub 2011 Oct 12.	Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression.	Dryhurst D, McMullen B, Fazli L, Rennie PS, AusiÅ@ J.	PMID:22055461
Biomaterials. 2012 Jan;33(2):692-703. doi: 10.1016/j.biomaterials.2011.09.081. Epub 2011 Oct 19.	Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder orthotumour.	Mugabe C, Raven PA, Fazli L, Baker JH, Jackson JG, Liggins RT, So AI, Gleave ME, Minchinton AI, Brooks DE, Burt HM.	PMID:22014457
Cancer Gene Ther. 2012 Jan;19(1):19-29. doi: 10.1038/cgt.2011.62. Epub 2011 Sep 16.	Fibroblast growth factor and ornithine decarboxylase 5'UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN(-/-) transgenic mice.	Moussavi M, Moshgabadi N, Fazli L, Leblanc E, Zhang K, Jia W, Rennie PS.	PMID:21921943
Int J Cancer. 2012 Jun 15;130(12):2835-44. doi: 10.1002/ijc.26287. Epub 2011 Sep 14.	Cardipoda abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression.	Wafa LA, Cheng H, Plaa N, Ghaidi F, Fukumoto T, Fazli L, Gleave ME, Cox ME, Rennie PS.	PMID:21780103
Cancer Res. 2011 Sep 17;71(17):5838-49. doi: 10.1158/0008-5472.CAN-11-0994. Epub 2011 Jul 7.	Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.	Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, Fazli L, Zoubeidi A, Gleave ME.	PMID:21737488

Details	Title	Authors	Identifiers
J Urol. 2011 Aug;186(2):465-9. doi: 10.1016/j.juro.2011.03.115. Epub 2011 Jun 15.	The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study.	McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD, Canary/Early Detection Research Network Prostate Active Surveillance Study Investigators.	PMID:21679996
EMBO J. 2011 May 20;30(13):2719-33. doi: 10.1038/emboj.2011.158.	The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis.	Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Warren A, Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, Osborne M, Hadfield J, Macarthur S, Adryan B, Lyons SK, Brindle KM, Griffiths J, et al.	PMID:21602788   PMCID:PMC3155295
Clin Cancer Res. 2011 Apr 15;17(8):2301-13. doi: 10.1158/1078-0432.CCR-10-3077. Epub 2011 Feb 24. Erratum in: Clin Cancer Res. 2011 Jul 15;17(14):4916.	A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.	Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeldi A.	PMID:21349995   PMCID:PMC4437585
Mol Cancer Ther. 2011 Feb;10(2):347-59. doi: 10.1158/1535-7163.MCT-10-0850. Epub 2011 Jan 7.	Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.	Thomas C, Zoubeldi A, Kuruma H, Fazli L, Lamoureux F, Beraldi E, Monia BP, MacLeod AR, Thakrroff JW, Gleave ME.	PMID:21216933
Nat Med. 2010 Dec;16(12):1414-20. doi: 10.1038/nm.2236. Epub 2010 Nov 7.	Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance.	Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE.	PMID:21057494   PMCID:PMC3088104
Clin Cancer Res. 2010 Sep 15;16(18):4675-80. doi: 10.1158/1078-0432.CCR-10-1113. Epub 2010 Jul 29.	Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists.	Liu SV, Schally AV, Hawes D, Xiong S, Fazli L, Gleave M, Cai J, Groshen S, Brands F, Engel J, Pinski J.	PMID:20670943
Prostate. 2010 Jul 1;70(10):1134-45. doi: 10.1002/pros.21148.	Relaxin drives Wnt signaling through upregulation of PCDH1 in prostate cancer.	Thompson VC, Hurtado-Coll A, Turbin D, Fazli L, Lehman ML, Gleave ME, Nelson CC.	PMID:20503398
Cancer Res. 2010 Mar 15;70(6):2307-17. doi: 10.1158/0008-5472.CAN-09-3252. Epub 2010 Mar 2. Erratum in: Cancer Res. 2011 Jul 15;71(14):5054.	Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD.	Zoubeldi A, Zardan A, Wiedmann RM, Locke J, Beraldi E, Fazli L, Gleave ME.	PMID:20197463   PMCID:PMC4437589
Mol Endocrinol. 2010 Apr;24(4):696-708. doi: 10.1210/me.2009-0229. Epub 2010 Feb 24.	TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domains.	Tavassoli P, Wafa LA, Cheng H, Zoubeldi A, Fazli L, Gleave M, Snoek R, Rennie PS.	PMID:20181722   PMCID:PMC5417532
Prostate. 2010 Jun 15;70(9):921-33. doi: 10.1002/pros.21126.	Inhibition of DHCR24/seladin-1 impairs cellular homeostasis in prostate cancer.	Battista MC, Guimond MO, Roberge C, Doueik AA, Fazli L, Gleave M, Sabbagh R, Gallo-Payet N.	PMID:20166102
Cancer Res. 2010 Feb 15;70(4):1367-76. doi: 10.1158/0008-5472.CAN-09-2377. Epub 2010 Feb 9.	Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice.	Moussavi M, Fazli L, Tearle H, Guo Y, Cox M, Bell J, Ong C, Jia W, Rennie PS.	PMID:20145134
Cancer. 2010 Apr 1;116(7):1699-708. doi: 10.1002/ncr.24960.	Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.	Garzotto M, Higano CS, O'Brien C, Rademacher BL, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM.	PMID:20143429   PMCID:PMC2846994
Oncogene. 2010 Apr 1;29(13):1883-96. doi: 10.1038/onc.2009.479. Epub 2010 Jan 18.	Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.	Andrieu C, Taieb D, Baylot V, Ettinger S, Soubeiran P, De-Thonel A, Nelson C, Garrido C, So A, Fazli L, Bladou F, Gleave M, Iovanna JL, Rocchi P.	PMID:20101233
Int J Cancer. 2010 Aug 15;127(4):830-8. doi: 10.1002/ijc.25088.	Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death.	Zhang KX, Matsui Y, Hadaschik BA, Lee C, Jia W, Bell JC, Fazli L, So AI, Rennie PS.	PMID:19957332
Prostate. 2010 Feb 15;70(3):239-51. doi: 10.1002/pros.21057.	Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.	Locke JA, Güns ES, Lehman ML, Ettinger S, Zoubeldi A, Lubik A, Margiotti K, Fazli L, Adomat H, Wasan KM, Gleave ME, Nelson CC.	PMID:19790237
Mol Cancer Ther. 2009 Aug;8(8):2402-11. doi: 10.1158/1535-7163.MCT-09-0148. Epub 2009 Jul 22.	Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer.	Matsui Y, Hadaschik BA, Fazli L, Andersen RJ, Gleave ME, So AI.	PMID:19625496
Cancer Gene Ther. 2009 Nov;16(11):820-31. doi: 10.1038/cgt.2009.28. Epub 2009 Apr 17.	Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells.	Zhang KX, Moussavi M, Kim C, Chow E, Chen IS, Fazli L, Jia W, Rennie PS.	PMID:19373278
Cancer Chemother Pharmacol. 2009 Nov;64(6):1085-95. doi: 10.1007/s00280-009-0965-1. Epub 2009 Mar 20.	Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy.	Musende AG, Eberding A, Wood C, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, Guns ET.	PMID:19301006
Prostate. 2009 Jun 15;69(9):928-37. doi: 10.1002/pros.20940.	A novel communication role for CYP17A1 in the progression of castration-resistant prostate cancer.	Locke JA, Fazli L, Adomat H, Smyl J, Weins K, Lubik AA, Hales DB, Nelson CC, Gleave ME, Tomlinson Guns ES.	PMID:19267349
Clin Cancer Res. 2009 Jan 1;15(1):39-47. doi: 10.1158/1078-0432.CCR-08-1726.	In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.	Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS.	PMID:19118031
Clin Cancer Res. 2008 Nov 1;14(21):6944-54. doi: 10.1158/1078-0432.CCR-08-0408.	Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer.	So AI, Levitt RJ, Eigi B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, Pollak M.	PMID:18980989
Clin Cancer Res. 2008 Sep 15;14(18):5769-77. doi: 10.1158/1078-0432.CCR-07-4282.	GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.	Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, Kim Y, Gleave ME.	PMID:18794086
Prostate. 2009 Jan 1;69(1):33-40. doi: 10.1002/pros.20852.	Insulin receptor expression by human prostate cancers.	Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M.	PMID:18785179
BMC Cancer. 2008 Aug 11;8:230. doi: 10.1186/1471-2407-8-230.	Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.	FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG.	PMID:18694509   PMCID:PMC2519091
J Urol. 2008 Sep;180(3):1161-6. doi: 10.1016/j.juro.2008.05.003. Epub 2008 Jul 18.	Investigation of a novel degradable ureteral stent in a porcine model.	Hadaschik BA, Paterson RF, Fazli L, Clinkscales KW, Shalaby SW, Chew BH.	PMID:18639278
Cancer Res. 2008 Jun 15;68(12):4506-10. doi: 10.1158/0008-5472.CAN-08-0238.	Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.	Hadaschik BA, Zhang K, So AI, Fazli L, Jia W, Bell JC, Gleave ME, Rennie PS.	PMID:18559493
Cancer Res. 2008 Jun 1;68(11):4352-9. doi: 10.1158/0008-5472.CAN-07-5237.	ASAP1, a gene at 8q24, is associated with prostate cancer metastasis.	Lin D, Watahiki A, Bayani J, Zhang F, Liu L, Ling V, Sadar MD, English J, Fazli L, So A, Gout PW, Gleave M, Squire JA, Wang YZ.	PMID:18519696
Prostate. 2008 Sep 1;68(12):1283-95. doi: 10.1002/pros.20783.	Effects of Egs knockdown on human prostate cancer xenograft growth and chemosensitivity.	Hayashi N, Koller E, Fazli L, Gleave ME.	PMID:18512732
BJU Int. 2008 Aug 5;102(5):610-6. doi: 10.1111/j.1464-410X.2008.07669.x. Epub 2008 Apr 2.	Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer.	Hadaschik BA, Jackson J, Fazli L, Zoubeldi A, Burt HM, Gleave ME, So AI.	PMID:18384625
BJU Int. 2008 Aug;102(3):389-97. doi: 10.1111/j.1464-410X.2008.07618.x. Epub 2008 Mar 11.	Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.	Sowery RD, Hadaschik BA, So AI, Zoubeldi A, Fazli L, Hurtado-Coll A, Gleave ME.	PMID:18336596
Clin Cancer Res. 2008 Mar 1;14(5):1510-8. doi: 10.1158/1078-0432.CCR-07-4475.	Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.	Hadaschik BA, Adomat H, Fazli L, Fradet Y, Andersen RJ, Gleave ME, So AI.	PMID:18316576
J Biol Chem. 2008 Feb 8;283(6):3349-56. Epub 2007 Dec 5.	The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.	Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L, Gleave ME, Qiu Y.	PMID:18056989
Cancer Res. 2007 Nov 1;67(21):10455-65.	Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity.	Zoubeldi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M.	PMID:17974989
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5. Epub 2007 Oct 2.	Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.	Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, Chaix A, Fazli L, Motoo Y, Wang Q, Rocchi P, Russo A, Gleave M, Dagnon JC, Iovanna JL, Carrier A, PÃ©busque MJ, Dusetti NI.	PMID:17911264   PMCID:PMC2042180
BJU Int. 2007 Dec;100(6):1377-84. Epub 2007 Sep 10.	A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging.	Hadaschik BA, Black PC, Sea JC, Metwalli AR, Fazli L, Dinney CP, Gleave ME, So AI.	PMID:17850390
Prostate. 2007 Nov 1;67(15):1621-9.	Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor protein-5 expression.	Xu C, Graf LF, Fazli L, Coleman IM, Mauldin DE, Li D, Nelson PS, Gleave M, Plymate SR, Cox ME, Torok-Storb BJ, Knudsen BS.	PMID:17823924
Cancer Res. 2007 May 15;67(10):5033-41.	Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.	Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS.	PMID:17510436
Cancer Res. 2007 May 15;67(10):4630-7.	DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells.	Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, Gleave M, Rennie PS, Kasper S.	PMID:17510388
Prostate. 2007 Jul 1;67(10):1038-52.	Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression.	Ghosh R, Gu G, Tillman E, Yuan J, Wang Y, Fazli L, Rennie PS, Kasper S.	PMID:17455228

Details	Title	Authors	Identifiers
BJU Int. 2007 May;99(5):1154-60. Epub 2007 Feb 19. Erratum in: BJU Int. 2007 May;99(5):1161. Fadzli, Ladan [corrected to Fazli, Ladan].	Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography.	Yapp DT, Woo J, Kartono A, Sy J, Oliver T, Skov KA, Koch CJ, Adomat H, Dragowska WH, Fazli L, Ruth T, Adam MJ, Green D, Gleave M.	PMID:17309552
Cancer Chemother Pharmacol. 2007 Nov;60(6):821-9.	Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts.	Low JC, Wasan KM, Fazli L, Eberding A, Adomat H, Guns ES.	PMID:17294190
J Clin Pathol. 2007 Nov;60(11):1238-43. Epub 2007 Jan 26.	Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.	Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG.	PMID:17259299   PMCID:PMC2095486
Prostate. 2006 Dec 1;66(16):1698-709.	Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens.	Thompson VC, Morris TG, Cochrane DR, Cavanagh J, Wafa LA, Hamilton T, Wang S, Fazli L, Gleave ME, Nelson CC.	PMID:16998820
Hum Pathol. 2007 Jan;38(1):161-70. Epub 2006 Sep 25.	Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.	Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, Rennie PS.	PMID:16997353
BJU Int. 2006 Nov;98(5):1082-9. Epub 2006 Jul 28.	Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro.	Rocchi P, Juggal P, So A, Sinneman S, Ettinger S, Fazli L, Nelson C, Gleave M.	PMID:16879439
Prostate. 2006 Sep 15;66(13):1445-54.	Clusterin is not essential for androgen-regulated involution and regeneration of the normal mouse prostate.	Fink D, Fazli L, Aronow B, Gleave ME, Ong CJ.	PMID:16865725
BJU Int. 2006 Jun;97(6):1300-8.	Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xl genes.	Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke U, Gleave ME.	PMID:16686729
J Urol. 2006 May;175(5):1926-31.	Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.	Xie X, Eberding A, Madera C, Fazli L, Jia W, Goldenberg L, Gleave M, Guns ES.	PMID:16600800
Prostate. 2006 Jun 15;66(9):971-86.	Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models.	Kojima S, Mulholland DJ, Ettinger S, Fazli L, Nelson CC, Gleave ME.	PMID:16541420
Prostate. 2006 Jun 15;66(9):895-902.	Loss of PTEN is associated with progression to androgen independence.	Bertram J, Peacock JW, Fazli L, Mui AL, Chung SW, Cox ME, Monia B, Gleave ME, Ong CJ.	PMID:16496415
Mol Cancer Ther. 2005 Dec;4(12):1837-49.	Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.	So A, Sinnemann S, Huntsman D, Fazli L, Gleave M.	PMID:16373699
Cancer Res. 2005 Dec 1;65(23):11083-93.	Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.	Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M.	PMID:16322258
Mol Cancer Ther. 2005 Nov;4(11):1689-98.	A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.	Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, Gleave ME.	PMID:16275990
Int J Cancer. 2006 Mar 1;118(5):1108-19.	Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer.	Ray MR, Wafa LA, Cheng H, Snoek R, Fazli L, Gleave M, Rennie PS.	PMID:16161052
J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96.	A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.	Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME.	PMID:16145049
Cancer Gene Ther. 2006 Jan 1;13(1):32-43.	Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter.	Yu D, Scott C, Jia WW, De Benedetti A, Williams BJ, Fazli L, Wen Y, Gleave M, Nelson C, Rennie PS.	PMID:16052226
Am J Pathol. 2005 Jul;167(1):255-66.	Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate.	Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE.	PMID:15972969   PMCID:PMC1603455
Cancer Res. 2004 Dec 1;64(23):8620-9.	Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.	Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME.	PMID:15574769
Cancer Res. 2004 Sep 15;64(18):6595-602.	Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.	Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M.	PMID:15374973
Mol Cancer Ther. 2004 Mar;3(3):223-32.	Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.	July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME.	PMID:15026542
Cancer Cell. 2004 Jan;5(1):79-90.	Regulation of tumor angiogenesis by integrin-linked kinase (ILK).	Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K, Wheeler J, Gleave M, Sanghera J, Dedhar S.	PMID:14749128
Pharmacol Ther. 2002 Feb-Mar;93(2-3):233-42. Review.	Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties.	Yoganathan N, Yee A, Zhang Z, Leung D, Yan J, Fazli L, Kojic DL, Costello PC, Jabali M, Dedhar S, Sanghera J.	PMID:12191615